

## REMARKS

### **I. Preliminary Remarks**

On November 27, 2006 Rosanne Goodman, an attorney from Pfizer's Patent Department, filed a reply to the previous Office action mailed 11/16/2007 issuing a restriction requirement in the present application, where amendments to claims 1, 4, and 13 were made. The amendments inadvertently deleted the entire definition of "R<sup>1</sup>" in claim 1 and a number of elected species in claim 13. Ms. Goodman informed the unsigned that she had a telephonic interview with Examiner Moore on April 13, 2007 regarding the previous Office action and the amendments she filed. According to Ms. Goodman, the Examiner clarified that the search and examination of the claims in the present Office action was based on the un-amended version of claim 4 having the original R<sup>1</sup> definition and, therefore, the Examiner has agreed that the original definition of R<sup>1</sup> may be reinstated. Further according to Ms. Goodman, the Examiner has suggested that no amendments be made to withdrawn claims 9 and 12, both of which show two substituent groups bearing a "strikethrough" mark. Applicants appreciated the Examiner's clarifications and suggestions, which have been relied upon in the present reply and amendment.

### **I. Status of the Claims**

Prior to the present amendment, claims 1-15 were pending in the application, among which claims 5, 8-12, and 15 were withdrawn. By this amendment claims 5, 7 - 12, and 15 are cancelled. After the entry of this amendment, claims 1-4, 6, 13, and 14 are pending.

### **II. Amendment to the Specification**

The title of the invention has been replaced with the title that is suggested by the Examiner.

### **III. Amendments to the Claims**

The following amendments have been made to claim 1: (1) The term "solvate" in the forth line of the claim and the extra phrase "at least one" in the definition of R<sup>1</sup> have

been deleted; (2) the term "nitrogen atom," which was added by the previous reply, has been replaced with the language "heteroatom selected from the group consisting of N, O, and S," which was part of original claim 1 but was deleted by the previous reply; (3) The term "core fused heteroaromatic" in the definition of R<sup>4</sup> and R<sup>6</sup> together has been replaced with the term "pyrimidyl moiety," which is consistent with the Examiner's suggestion.

Claim 4 has been amended to reinstate the original definition of R<sup>1</sup> per agreement of the Examiner.

Claim 6 has been amended to exclude the non-elected subject matter.

Claims 7 – 12, and 15 are cancelled.

Claim 13 has been amended to remove the non-elected species and to reinstate the elected species that had been inadvertently removed by the reply filed on November 27, 2006.

The amendments have added no new matter. Applicants preserve the right to pursue the cancelled subject matter in other applications.

#### **IV. Claim Objections**

Claim 1 is objected to because of the extra phrase "at least one." This phrase has been deleted from the claim by this amendment.

Claims 1, 6, 7, and 13 are objected to allegedly because they contain non-elected subject matter. Claims 1, 6, and 13 have been amended to remove the subject matter in question and claim 7 cancelled.

The above amendments have overcome the objections.

#### **V. Claim Rejections under 35 U.S.C. §112**

Claim 15 is rejected under 35 U.S.C. §112, first paragraph, as allegedly failing to comply with the enablement requirement. In addition, claims 1-4, 6, 14, and 15 are rejected under 35 U.S.C. §112, first paragraph, as allegedly failing to comply with the enablement requirement with respect to the "solvates." For the sole purpose of expediting the allowance of the application Applicants have cancelled claim 15 in its

Appl. No. 10/783,251  
Amdt. Dated April 20, 2007  
Reply to Office action of January 24, 2007

entirety and deleted the term "solvates" from claim 1. The amendments have overcome the rejection.

Appl. No. 10/783,251  
Amdt. Dated April 20, 2007  
Reply to Office action of January 24, 2007

**VI. Concluding Remarks**

In view of the amendments and the foregoing remarks, Applicants respectfully request reconsideration of the matter and the withdrawal of all the rejections and objections. Applicants believe that the application is now in order for allowance and, accordingly, respectfully request timely issuance of a Notice of Allowance.

Respectfully submitted,

Date: April 20, 2007



---

Austin W. Zhang  
Reg. No. 48,061  
Warner-Lambert Company LLC  
2800 Plymouth Road  
Ann Arbor, MI 48105  
Customer No. 28880

Tel: (734) 622-5035  
Fax: (734) 622-1553